Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease

Kidney Research and Clinical Practice
Derek S Larson, Daniel W Coyne

Abstract

Hepcidin, produced by the liver, is the master regulator of iron balance. Serum hepcidin is increased by high iron stores, blocks intestinal iron absorption, and impairs storage iron release. Conversely, iron deficiency lowers hepcidin levels and enhances intestinal iron absorption and the release of storage iron. As with ferritin, hepcidin is an acute phase reactant. Consequently, inflammation increases hepcidin and leads to impaired iron absorption, lowers serum iron and transferrin saturation, and contributes to the anemia of chronic kidney disease (CKD). We review the physiology of iron absorption, its relationship to hepcidin and the transmembrane iron transporter ferroportin, the role of hepcidin in CKD related anemia, and the possible diagnostic implications and limitations of using hepcidin as a marker of iron status.

Citations

Sep 15, 2017·Kidney Research and Clinical Practice·Patrick Biggar, Gheun-Ho Kim
Aug 17, 2020·Pediatric Transplantation·Çiğdem OruçFatma Lale Sever
May 5, 2021·Molecular and Cellular Biochemistry·Rengin Elsurer AfsarBaris Afsar

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.